Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity

StudyGovernment health research

Source type: Study
Access type: Abstract/index
Publisher: The Lancet / PubMed
Indexed by: PubMed
Date: 2026
Added: 2026-06-19

Trust profile

VV Source Trust Matrix v1.0

VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.

Government health research

Publisher type: Government research
Bias profile: Low

This source is strongest for safety and clinical outcomes and weaker for consumer context and regulatory status.

VV Source Fit Score 1.0

Fit by use case

Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.

Frameworks ->

Regulatory status: 66/100; Context Source
Clinical outcomes: 90/100; Primary Anchor
Mechanism: 90/100; Primary Anchor
Safety: 92/100; Primary Anchor
Consumer context: 88/100; Strong Support
Trial discovery: 89/100; Strong Support

Best used for

Research synthesis
Public-health context
Safety resources

Weak for

Primary endpoint extraction when a study is available

Used in Viral Vitalism

Primary sourcesignal9 references

GLP-1s, Dopamine, and Addiction: The Substance Use Signal

Roles: Primary source

Show section-level references

Primary sourcestudy1 reference

Roles: Primary source

Show section-level references

Semaglutide AUD + Obesity

Claim ledger

Claims supported

Reviewed claim cards that cite this source in the evidence graph.

uncertain79/100

glp 1: Early randomized human studies suggest GLP-1 receptor agonists may

Early randomized human studies suggest GLP-1 receptor agonists may reduce some alcohol craving or drinking outcomes, but the evidence is not yet sufficient for routine addiction treatment.

Early human evidence3 sources